or search for allinseo plug in" Body Health Advisor » Advice on Health and Body Matters

Archive for August, 2009

Insulin patch for Diabetics

Friday, August 21st, 2009

For Diabetics who need to enure the pain and discipline required in the use or injection pens, the following article is nice to know…read more below…

Medingo’s insulin patch approved; shares rocket

By Nick Taylor, 30-Jul-2009

Medingo’s insulin dispensing patch has been approved by the US Food and Drug Administration (FDA), sending shares in its parent company soaring to a 12 month high.

The company claims the patch, called Solo, is the smallest, thinnest, lightest and most discrete insulin pump without cumbersome tubing. Solo consists of two components: an insulin dispensing patch and a remote control.

Using the remote patients can customise the patch’s output to match their insulin needs. Gaining approval for the patch is regarded as a major milestone by Arie Mientkavich, chairman of Medingo.

Solo is set to be showcased at the American Association of Diabetes Educators Meeting, which takes place in Atlanta, US in August 2009. Mientkavich said the Medingo is “currently considering alternatives for its go-to-market strategy and the timing of the product launch”.

Release of the news sent the share price of Medingo’s parent company, Elron Electronics Industries, up by 56.4 per cent. The rise demonstrates investors’ belief in the opportunities that exist for products that deliver insulin in a more convenient way.

Sustained growth

Approval of Medingo’s Solo patch coincided with the release of a report into the transdermal drug delivery market by Greystone Associates.

The report predicts a period of sustained growth for the transdermal drug delivery market and highlights some areas other than diabetes where the technology is effective.

In particular the report believes that transdermal patches will be useful for the elderly, who tend to be less able to self-medicate than other patients groups. The aging population means that this will provide an increasingly large market.

To achieve a sustainable growth model, which the report says has so far eluded the transdermal delivery sector, Greystone predicts companies will pursue two strategies.

Firstly companies will achieve growth by increasing market penetration in key transdermal therapeutic segments by refining product strategies. A second source of growth will come from companies seeking to extend product lifecycles in the face of patent expiration.

The report believes that growth can be achieved by expanding into new therapeutic areas and working with companies that market patent protected products.

FDA Issues Pharmaceutical Industry Guidance on Preventing Melamine Contamination

Friday, August 14th, 2009

I was shocked to hear that melamine was found in infant’s milk powder manufactured in China. How can these manufacturers not consider the harm to innocent babies who rely on milk as their only source of nutrition? Not only is this happening in China, the very fact that unscrupulous activities can deceive the public is frightening. Hence, the FDA has taken the right approach not to assume anything. Here’s the latest excerpt from FDA on this matter…..


In a guidance issued 6 Aug 2009, the U.S. Food and Drug Administration says that certain pharmaceutical ingredients used in the manufacture or preparation of drug products should be tested for melamine.

Melamine is a synthetic chemical with a variety of industrial uses including the production of resins and foams, cleaning products, fertilizers and pesticides. If ingested in sufficient amounts, melamine can result in kidney failure and death.

Although the FDA has no reason to believe that the U.S. pharmaceutical supply is contaminated with melamine, recent events involving pet and livestock food products in the United States, and milk products for infants in China, underscore the potential problem.

The guidance is an initial measure by the agency in working with pharmaceutical manufacturers, repackers, other suppliers and pharmacists to conduct melamine testing. The agency invites comments on the guidance, available online and titled “Guidance for Industry: Pharmaceutical Components At Risk for Melamine Contamination“.

“The FDA urges implementation of appropriate controls to assure consumers that melamine contamination will not happen in the pharmaceutical supply chain,” said Commissioner of Food and Drugs Margaret A. Hamburg, M.D. “We look forward to working with industry on this serious public health concern.”

The FDA identifies specific pharmaceutical ingredients in the guidance that are recommended to be screened for the presence of melamine. The guidance also recommends the use of FDA-published methods for this testing that are used to detect the presence of melamine in food proteins. These tests rely on equipment that is generally available to pharmaceutical manufacturers or contract testing labs. The agency also is developing a sampling and testing program for pharmaceutical ingredients at risk for melamine contamination.

RSS Feed for FDA News Releases

Technorati Tags:

Diabetics - If you are taking Levemir, take note

Sunday, August 9th, 2009

I saw this article, first published in June 13 2009 and felt it important to share….

FDA Issues Public Health Advisory Regarding Levemir Insulin

The U.S. Food and Drug Administration has learned that some stolen vials of the long-acting insulin Levemir made by Novo Nordisk Inc. have reappeared and are being sold in the U.S. market. Three lots or a total of 129,000 vials of this product were stolen in all. These stolen insulin vials may not have been stored and handled properly and may be dangerous for patients to use.

The FDA has received one report of a patient who suffered an adverse event due to poor control of glucose levels after using a vial from one of these three lots.

The agency is advising patients who use Levemir insulin to:

1. Check your personal supply of insulin to determine if you have Levemir insulin from one of the following lots: XZF0036, XZF0037, and XZF0038. Patients can locate the lot number on the side of the box of insulin and also on the side of the vial.

2. Do not use your Levemir insulin if it is from one of these lots. Replace it with a vial of Levemir insulin from another lot. If you must switch to another brand of insulin for any reason, first contact your healthcare provider as another insulin product may require adjustments in dosing.

3. Always visually inspect your insulin before using it. Levemir is a clear and colorless solution.

4. Contact the Novo Nordisk Customer Care Center at 800-727-6500 for what to do with vials from these lots or if you have any other questions.

For more information:
Novo Nordisk news release

Technorati Tags:

FDA: Tuna Salad Sandwiches, Other Products Seized at Louisiana Company

Sunday, August 9th, 2009

Here’s some shocking news about unsanitary conditions which I would like to share….. here’s what the FDA article on 7 August 2009 states:

At the request of the U.S. Food and Drug Administration, U.S. Marshals today seized tuna salad sandwiches and other food products from Bearden Sandwich Company Inc., doing business as Southern Belle Sandwich Company, in Baton Rouge, La.

The seized products, totaling more than $72,000, violate the Federal Food, Drug, and Cosmetic Act because the products have been prepared, packed, and held under unsanitary conditions whereby they may have become contaminated with filth or rendered injurious to the public’s health (the Act uses the term “insanitary” to describe such conditions). In addition, the tuna fish salad sandwiches were processed under conditions that violate Seafood Hazard Analysis Critical Control Point (HACCP) regulations.

“When FDA investigators find violations inside a company’s facility, we will do what is necessary to keep insanitary and potentially harmful products out of consumers’ hands,” said Michael Chappell, the FDA’s acting associate commissioner for regulatory affairs. “Companies that are not complying with our laws will be subject to enforcement actions.”

Recent FDA inspections found evidence of widespread and active rodent and insect infestation, filthy conditions, and poor employee practices, such as allowing food-processing utensils to lie on the floor near live insects.

The company distributes products to convenience and retail stores in southern Louisiana; Mobile, Ala.; Montgomery, Ala.; and Crestview, Fla.

The FDA has not received reports of illnesses associated with consumption of the products. The FDA urges consumers who may have purchased the products to dispose of them in a safe manner and wash their hands thoroughly after handling the products. “Safe disposal” means avoiding bare-hand contact with the recalled products, discarding them in a way that will not allow people and pets to retrieve them, and washing items that came in contact with the products, including hands, with warm, soapy water.
Consumers can also report problems, including adverse reactions, to the FDA district office consumer complaint coordinator.

Technorati Tags:

  • A possible replacement of Rosiglitazone and Pioglitazone for Type II Diabetes?
    Findings from the Phase II SYNCHRONY study show that aleglitazar, a treatment for Type 2 diabetes, could be safe and effective and thus will be entered into Phase III trials. The data, already published online and forthcoming in The Lancet, were presented at the recent American Diabetes Association meeting in New Orleans, La. Aleglitazar is in [...]
  • New Hope for Type II Diabetics
    GlaxoSmithKline in February announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety, and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria® (albiglutide) in men and women with type 2 diabetes. The Phase III program will include more than 4,000 patients […]
  • New Studies on Weight Loss Drug - promising results
    I know that many chronic obese people rely on Weight loss drugs to control their weight. No doubt despite the side effects, some people have really tried everything to natuarally lose weight, but to no avail. With a doctor’s advice, they resort to medication. These naturally come with side effects, and sometimes are not even [...]
  • Warning about Venom HYPERDRIVE 3.0 supplements
    FDA Warns Consumers Against Dietary Supplement Containing Undeclared Drug Product poses safety risk The U.S. Food and Drug Administration is warning consumers not to take Venom HYPERDRIVE 3.0, a product sold as a dietary supplement and containing sibutramine. Sibutramine, a controlled substance with risks for abuse or addiction, is a potent drug [...]
Pages
H1N1 Fraudulent Products update







Tai Chi WeightLoss